Empirical therapy for severe infection of diabetes-related foot ulcers

For patients with severe infection of a diabetes-related foot ulcer who have sepsis or septic shock, start antibiotic therapy within 1 hour of presentation to medical care or, for ward-based patients, development of sepsis or septic shock. Antibiotics should be administered immediately after blood samples are taken for culture. Collect deep tissue samples as soon as possible; however, do not delay antibiotic administration or surgery to do so. For nonantibiotic management of sepsis or septic shock, see Resuscitation of patients with sepsis or septic shock.

Urgent early surgical advice is recommended for patients with severe infection of a diabetes-related foot ulcer, including patients with extensive gangrene, necrotising infection, signs suggesting deep infection or abscess, or severe lower limb ischaemiaCommons, 2021. For additional management considerations, see Approach to managing infection of diabetes-related foot ulcers.

Note: Urgent early surgical advice is recommended for patients with severe infection of diabetes-related foot ulcers.

For patients with severe infection of a diabetes-related foot ulcer who are at low risk of methicillin-resistant Staphylococcus aureus (MRSA) infection (see Risk factors for infection with methicillin-resistant Staphylococcus aureus), use:

piperacillin+tazobactam intravenously. For dosage adjustment in adults with kidney impairment, see piperacillin+tazobactam dosage adjustment. See advice on duration of therapy piperacillin + tazobactam piperacillin+tazobactam piperacillin+tazobactam

patients without septic shock and not requiring intensive care support: 4+0.5 g 6-hourly1

patients with septic shock or requiring intensive care support: 4+0.5 g administered over 30 minutes. After 3 hours, start a continuous infusion of 16+2 g administered over 24 hours23.

For patients with hypersensitivity to penicillins who are at low risk of MRSA infection (see Risk factors for infection with methicillin-resistant Staphylococcus aureus), as a 2-drug regimen, use:

ciprofloxacin 400 mg intravenously, 8-hourly. For dosage adjustment in adults with kidney impairment, see ciprofloxacin intravenous dosage adjustment. See advice on duration of therapy ciprofloxacin ciprofloxacin ciprofloxacin

PLUS

clindamycin 600 mg intravenously, 8-hourly. See advice on duration of therapy4. clindamycin clindamycin clindamycin

For patients who have severe limb- or life-threatening infection, or those at increased risk of MRSA infection, add vancomycin to the above regimens. Use:

vancomycin intravenously; see Vancomycin dosing in adults for initial dosing. Loading doses are recommended for critically ill adults. See advice on duration of therapy. vancomycin vancomycin vancomycin

Modify therapy based on the results of culture and susceptibility testing. If culture and susceptibility results are not available by 72 hours and the patient is clinically improving, use a regimen for moderate infection of diabetes-related foot ulcers for ongoing therapy. It is not necessary to continue treatment active against Pseudomonas aeruginosa or MRSA if they are not identified on culture.

If prolonged intravenous antibiotic therapy is required in patients who are clinically stable, consider intravenous ambulatory antimicrobial therapy.

1 Administration of piperacillin+tazobactam over 3 hours may be preferred to ensure adequate drug exposure for Pseudomonas aeruginosa. For more information, see Practical information on using beta lactams: penicillins.Return
2 In patients with septic shock or requiring intensive care support, administering the total daily dose of piperacillin+tazobactam over 24 hours is preferred to ensure adequate drug exposure. However, when this is not possible (eg the patient is receiving other drugs via the same line), administer the dose as an extended infusion over 3 hours or as a bolus over 30 minutes. For more information, see Practical information on using beta lactams: penicillins.Return
3 The modified dosage of piperacillin+tazobactam for patients with septic shock or those requiring intensive care support is recommended to ensure adequate drug exposure, because pharmacokinetics may be altered in patients with critical illness (eg because of enhanced kidney clearance or changes in volume of distribution). Once the critical illness has resolved, consider switching to the standard dosage. Return
4 There are more clinical and microbiological data to support the use of clindamycin than lincomycin. Intravenous lincomycin can be used at the same dosage if clindamycin is unavailable or if a local protocol recommends its use.Return